Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44020   clinical trials with a EudraCT protocol, of which   7318   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-000378-38
    Sponsor's Protocol Code Number:PB-102-F20
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-07-15
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-000378-38
    A.3Full title of the trial
    A Randomized, Double blind, Active Control Study of the Safety and Efficacy of PRX-102 compared to Agalsidase Beta on Renal Function in Patients with Fabry Disease Previously Treated With Agalsidase
    Beta
    Estudio aleatorizado, doble ciego, con control activo de la seguridad y la eficacia de PRX-102 en comparación con agalsidasa beta en la función renal en pacientes con enfermedad de Fabry previamente tratados con agalsidasa beta
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Safety and effectiveness study comparing PRX-102 and Agalsidase Beta on Kidney function for patients with Fabry Disease who have previously been treated with Agalsidase Beta
    Estudio de eficacia y seguridad comparando PRX-102 y Agalsidasa Beta en la función renal en los pacientes con enfermedad de Fabry que previamente han sido tratados con Agalsidasa Beta
    A.4.1Sponsor's protocol code numberPB-102-F20
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorProtalix Ltd.
    B.1.3.4CountryIsrael
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportProtalix Ltd.
    B.4.2CountryIsrael
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationProtalix Ltd.
    B.5.2Functional name of contact pointRaul Chertkoff
    B.5.3 Address:
    B.5.3.1Street Address2 Snunit St, Science Park, POB 455
    B.5.3.2Town/ cityCarmiel
    B.5.3.3Post code20100
    B.5.3.4CountryIsrael
    B.5.4Telephone number+3497Estudio de eficacia y segurida
    B.5.6E-mailraul@protalix.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePegunigalsidase alfa
    D.3.2Product code PRX-102
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPegunigalsidase alpha
    D.3.9.1CAS number 1333358-30-7
    D.3.9.2Current sponsor codePRX-102
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fabrazyme
    D.2.1.1.2Name of the Marketing Authorisation holderGenzyme Europe B.V.
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFabrazyme
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAGALSIDASE BETA
    D.3.9.1CAS number 104138-64-9
    D.3.9.2Current sponsor codeN/A
    D.3.9.3Other descriptive nameN/A
    D.3.9.4EV Substance CodeSUB12457MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number35
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Fabrazyme
    D.2.1.1.2Name of the Marketing Authorisation holderGenzyme Europe B.V.
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFabrazyme
    D.3.4Pharmaceutical form Powder for concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNAGALSIDASE BETA
    D.3.9.1CAS number 104138-64-9
    D.3.9.2Current sponsor codeN/A
    D.3.9.3Other descriptive nameN/A
    D.3.9.4EV Substance CodeSUB12457MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Fabry disease (α-galactosidase A deficiency)
    Enfermedad de Fabry (déficit de alfa-galactosidasa)
    E.1.1.1Medical condition in easily understood language
    Fabry disease
    Enfermedad de Fabry
    E.1.1.2Therapeutic area Body processes [G] - Genetic Phenomena [G05]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10016016
    E.1.2Term Fabry's disease
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
    Evaluar la seguridad y la eficacia de PRX-102 en comparación con
    agalsidasa beta en pacientes con enfermedad de Fabry y disfunción renal
    E.2.2Secondary objectives of the trial
    N/A
    NA
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacokinetics (PK) sub-study.
    Sub-estudio de Farmacocinética (PK)
    E.3Principal inclusion criteria
    Eligible subjects must fulfill the following inclusion criteria:
    1. Symptomatic adult Fabry disease patients, age 18-60 years
    a. Plasma and/or leucocyte alpha galactosidase activity (by activity assay) less than 30% mean normal levels
    b. One or more of the described characteristic features of Fabry disease:
    i. neuropathic pain,
    ii. cornea verticillata,
    iii. clustered angiokeratoma
    2. Screening eGFR by CKD-EPI equation 40 to 90 mL/min/1.73 m2
    3. Linear negative slope of eGFR of ≥ 2 mL/min/1.73 m2 based on at least 3 serum creatinine values over approximately 1 year (range of 9 to 18 months, including the value obtained at the screening visit)
    4. Treatment with a dose of 1 mg/kg agalsidase beta per infusion every 2 weeks for at least one year and at least 80% of 13 (10.4) mg/kg total dose over the last 6 months
    5. Female patients and male patients whose co-partners are of child-bearing potential agree to use a medically accepted method of contraception, not including the rhythm method.
    Para ser aptos, los sujetos deben cumplir los siguientes criterios de inclusión:
    1. Pacientes con enfermedad de Fabry sintomática, con edades entre 18 y 60 años.
    a. Actividad de la alfa-galactosidasa en el plasma o en los leucocitos (mediante análisis de actividad) de menos del 30 % de los valores normales medios.
    b. Uno o varios de los rasgos característicos descritos de la enfermedad de Fabry:
    i. dolor neuropático,
    ii. córnea verticillata,
    iii. angioqueratomas en grupos.
    2. TFGe en la selección mediante la ecuación CKD-EPI de 40 a 90
    ml/min/1,73 m2.
    3. Pendiente lineal negativa de la TFGe de ≥ 2 ml/min/1,73 m2 en
    función de al menos 3 valores de creatinina en suero en
    aproximadamente 1 año (intervalo de 9 a 18 meses, incluido el valor obtenido en la visita de selección).
    4. Tratamiento con una dosis de 1 mg/kg de agalsidasa beta por infusión cada 2 semanas durante al menos un año y al menos un 80 % de la dosis total de 13 (10,4) mg/kg en los últimos 6 meses.
    5. Pacientes de sexo femenino y masculino cuyas parejas estén en edad fértil y acepten el uso de un método anticonceptivo aceptado desde el punto de vista médico, sin incluir el método del ritmo.
    E.4Principal exclusion criteria
    The presence of any of the following excludes a subject from study enrollment:
    1. History of anaphylaxis or Type 1 hypersensitivity reaction to agalsidase beta
    2. History of renal dialysis or transplantation
    3. History of acute kidney injury in the 12 months prior to screening, including specific kidney diseases (e.g., acute interstitial nephritis, acute glomerular and vasculitic renal diseases); non-specific conditions (e.g, ischemia, toxic injury); as well as extrarenal pathology (e.g., prerenal azotemia, and acute postrenal obstructive nephropathy)
    4. Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy initiated or dose changed in the 4 weeks prior to screening
    5. Urine protein to creatinine ratio (UPCR) > 0.5 g/g and not treated with an ACE inhibitor or ARB
    6. Cardiovascular event (myocardial infarction, unstable angina) in the 6 month period before randomization
    7. Congestive heart failure NYHA Class IV
    8. Cerebrovascular event (stroke, transient ischemic attack) in the 6 month period before randomization
    9. Known history of hypersensitivity to Gadolinium contrast agent
    10. Female subjects who are pregnant, planning to become pregnant during the study, or are breastfeeding
    11. Presence of any medical, emotional, behavioral or psychological condition that, in the judgment of the Investigator and/or Medical Director, would interfere with the patient’s compliance with the requirements of the study
    La presencia de alguno de los criterios siguientes excluye al sujeto de la inscripción en el estudio:
    1. Antecedentes de anafilaxis o reacción de hipersensibilidad de tipo 1 a la agalsidasa beta.
    2. Antecedentes de diálisis o trasplante renal.
    3. Antecedentes de lesión renal aguda en los 12 meses anteriores a la selección, incluidas nefropatías específicas (p. ej., nefritis intersticial aguda, enfermedades renales glomerulares y vasculares agudas);
    afecciones inespecíficas (p. ej., isquemia, lesión tóxica); así como
    patología extrarrenal (p. ej., azotemia prerrenal y nefropatía obstructiva postrenal).
    4. Tratamiento con inhibidor de la enzima de conversión de la
    angiotensina (ECA) o bloqueador del receptor de la angiotensina (BRA) iniciado o dosis cambiada en las 4 semanas previas a la selección.
    5. Cociente proteínas/creatinina en orina (UPCr) > 0,5 g/g y no tratado con un inhibidor de la ECA ni un BRA.
    6. Acontecimiento cardiovascular (infarto de miocardio, angina
    inestable) en el periodo de 6 meses previo a la aleatorización.
    7. Insuficiencia cardiaca congestiva de clase IV de la NYHA.
    8. Acontecimiento cerebrovascular (ictus, accidente isquémico
    transitorio) en el periodo de 6 meses previo a la aleatorización.
    9. Antecedentes conocidos de hipersensibilidad a un medio de contraste con gadolinio.
    10. Sujetos de sexo femenino que estén embarazadas, planeen quedarse embarazadas durante el estudio o que estén en periodo de lactancia.
    11. Presencia de cualquier problema médico, emocional, conductual o psicológico que, a juicio del investigador o del director médico, interferiría en el cumplimiento del paciente de los requisitos del estudio.
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy parameter is the comparison of the mean annualized change (slope) in estimated glomerular filtration rate (eGFRCKD-EPI) between treatment groups.

    Safety endpoints:
    Changes from baseline in:
     Clinical laboratory tests
     Physical examination
     Assessment of the injection site
     ECG
     Treatment-emergent adverse events
     Ability to taper off infusion pre-medication throughout the first 3 months of the study
     Requirement for use of pre-medication overall to manage infusion reactions
     Treatment-emergent anti-PRX-102 antibodies
     Treatment-emergent anti-agalsidase beta antibodies
    El parámetro principal de la eficacia es la comparación del cambio medio anualizado (pendiente) en la tasa de filtración glomerular estimada (TFGe-CKD-EPI) entre grupos de tratamiento.
    Criterios de valoración de la seguridad:
    • Análisis clínicos
    • Exploración física
    • Evaluación de la zona de inyección
    • ECG
    • Acontecimientos adversos surgidos durante el tratamiento
    • Capacidad para disminuir de forma gradual la premedicación para la
    infusión a lo largo de los primeros 3 meses del estudio
    • Requisito de uso de la premedicación en general para tratar las
    reacciones a la infusión
    • Anticuerpos anti-PRX-102 surgidos durante el tratamiento
    • Anticuerpos anti-agalsidasa beta surgidos durante el tratamiento
    E.5.1.1Timepoint(s) of evaluation of this end point
    Efficacy will be determined by the slope of eGFR over the course of the study. Two analyses of efficacy will be performed – at 12 and 24 months of treatment

    The eGFR endpoint is calculated based on serum creatinine and the serum creatinine will be collected in the following visits - screening
    - V1 baseline
    - All odd numbered visits
    La eficacia se determina por la pendiente de TFGe en el transcurso del estudio. Dos análisis de eficacia se llevarán a cabo a los 12 y 24 meses de tratamiento El punto final de TFGe se calcula en función de la creatinina en suero y la
    creatinina en suerose recoge en las siguientes:
    visitas de screening
    - V1 línea de inicio
    - Todas las visitas impare
    E.5.2Secondary end point(s)
    Secondary efficacy endpoints:
     Left Ventricular Mass Index (g/m2) by MRI
     Plasma Lyso-Gb3
     Plasma Gb3
     Urine Lyso-Gb3
     Protein/Creatinine ratio spot urine test
     Frequency of pain medication use
     Exercise tolerance (Stress Test)
     Short Form Brief Pain Inventory (BPI)
     Mainz Severity Score Index (MSSI)
     Quality of life EQ-5D-5L
    Criterios secundarios de valoración de la eficacia:
    • Índice de masa del ventrículo izquierdo (g/m2) mediante RM
    • Lyso-Gb3 en plasma
    • Gb3 en plasma
    • Lyso-Gb3 en orina
    • Cociente proteínas/creatinina en prueba puntual de orina
    • Frecuencia de uso de analgésicos
    • Tolerancia al ejercicio (prueba de esfuerzo)
    • Cuestionario abreviado para la evaluación del dolor (Brief Pain
    Inventory, BPI)
    E.5.2.1Timepoint(s) of evaluation of this end point
    In addition to the primary efficacy comparison described above, a series of secondary efficacy analyses will be performed to compare groups on the secondary outcomes of interest.
    Además de la comparación de la eficacia principal descrita
    anteriormente, se realizará una serie de análisis secundarios de la
    eficacia para comparar los grupos en cuanto a los resultados de interés
    secundarios.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    Czech Republic
    Germany
    Hungary
    Netherlands
    Norway
    Paraguay
    Spain
    Turkey
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Ultima visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 78
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 39
    F.4.2.2In the whole clinical trial 78
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects with the option to be enrolled in an open-label extension study upon completion of the study. Agalsidase beta patients are eligible for treatment in the extension study with pegunigalsidase alfa (PRX- 102) 1 mg/kg.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-08-22
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-07-27
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA